BWA
BBIO icon

Basecamp Wealth Advisors’s BridgeBio Pharma BBIO Stock Holding History

Basecamp Wealth Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.99K Hold
67
– – ﹤0.01% 1178
2026
Q1 		$4.97K Sell
67
-33
-33% -$2.39K ﹤0.01% 1186
2025
Q4 		$7.65K Buy
+100
New +$6.56K ﹤0.01% 1046

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Basecamp Wealth Advisors's BBIO Position: Q2 2026 in Review

Basecamp Wealth Advisors held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 67 shares worth $4.99K. The position accounts for ﹤0.01% of the portfolio, ranked #1178.

Basecamp Wealth Advisors first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.65K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Basecamp Wealth Advisors held 67 shares of BridgeBio Pharma worth $4.99K as of Q2 2026.
  • Basecamp Wealth Advisors left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1178 holding.
  • Basecamp Wealth Advisors first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's BridgeBio Pharma position peaked at $7.65K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.